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Abstract: Animal-derived antivenoms constitute the mainstay in the therapy of snakebite
envenoming. The efficacy of antivenoms to neutralize toxicity of medically-relevant snake venoms
has to be demonstrated through meticulous preclinical testing before their introduction into the
clinical setting. The gold standard in the preclinical assessment and quality control of antivenoms
is the neutralization of venom-induced lethality. In addition, depending on the pathophysiological
profile of snake venoms, the neutralization of other toxic activities has to be evaluated, such as
hemorrhagic, myotoxic, edema-forming, dermonecrotic, in vitro coagulant, and defibrinogenating
effects. There is a need to develop laboratory assays to evaluate neutralization of other relevant venom
activities. The concept of the 3Rs (Replacement, Reduction, and Refinement) in Toxinology is of
utmost importance, and some advances have been performed in their implementation. A significant
leap forward in the study of the immunological reactivity of antivenoms against venoms has been
the development of “antivenomics”, which brings the analytical power of mass spectrometry to the
evaluation of antivenoms. International partnerships are required to assess the preclinical efficacy
of antivenoms against snake venoms in different regions of the world in order to have a detailed
knowledge on the neutralizing profile of these immunotherapeutics.
Keywords: antivenoms; snake venoms; neutralization tests; preclinical efficacy; antivenomics; the 3Rs
1. Introduction
Snakebite envenoming is a neglected tropical disease that exerts a high burden of mortality
and morbidity, particularly in impoverished rural regions of Africa, Asia, Latin America and parts
of Oceania [1–3]. Administration of animal-derived antivenoms is the only scientifically-validated
therapy for these envenomings ever since the development of the first serum antivenimeux by Albert
Calmette, and following studies of [4,5]. The technology of antivenom manufacture experienced
a series of improvements in the 20th century, with the introduction of fractionation protocols aimed
at generating purified preparations of whole IgG or, alternatively, of the immunoglobulin fragments
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F(ab’)2 or Fab [6]. Currently, there is a heterogeneous universe of antivenom manufacturers in all
continents, but limitations in antivenom availability and accessibility in various parts of the world,
especially in sub-Saharan Africa and parts of Asia, constitute a significant public health problem [7–9].
In contrast to other immunoglobulin preparations used for passive immunization, such as tetanus
antitoxin and anti-rabies immunoglobulins, in which the antigens to be neutralized by antibodies
present little variability regardless of geographical location, antivenoms for snakebite envenomings
differ in their specificity depending on the particular venoms being used for immunization. There is
a large variation in snake venom composition at all taxonomic levels, including genera, species,
and even between and within populations and individuals of the same species [10,11]. Moreover,
a complex pattern of ontogenetic shifts in venom composition has been described for the venoms
of some species, hence opening another level of variation [12–15]. Thus, despite the fact that snake
venoms are generally constituted by a limited number of protein families, there are variations in the
proportion of each type of protein family in different venoms and, within a single protein family,
there are many iso- and proteoforms with distinct toxicological and immunological profiles [16–18].
Elapid snake venoms are predominantly composed of neurotoxins or cytotoxins of the three-finger
toxin family and phospholipases A2 (PLA2) [19–21]. Viperid venoms, in contrast, are composed mostly
of PLA2s, zinc-dependent metalloproteinases (SVMPs) and serine proteinases (SVSPs) [22]. Venoms of
stiletto snake species of the subfamily Atractaspidinae, are rich in sarafotoxins [23], whereas those of
species of the highly diverse non-front-fanged group of the family Colubridae contain variable sets of
protein families [24]. In addition to these predominant protein types, venoms of the various snake
families contain other components that, albeit generally minor, may play key roles in toxicity, such as
C-type lectin-like proteins, disintegrins, vasoactive peptides, hyaluronidase, cysteine-rich secretory
proteins (CRISPs), and low molecular mass myotoxins among others [22,25].
Such biochemical, and consequently immunological, diversity constitutes a great challenge for
antivenom design, manufacture and quality control. An antivenom effective against a group of venoms
in a particular country may not be effective against other venoms of relevance in the same country,
or against venoms of species from another region. This phenomenon has had a significant impact
in public health since, owing to deficient regulatory control, some antivenoms have been exported
to countries where they are not effective (see for example [26]). Frequently, antivenoms have been
introduced to countries without a robust preclinical evaluation of their efficacy against the medically
most relevant venoms [8,27]. The design of venom mixtures for immunization aimed at antivenom
production has been largely based on empirical criteria and not on a rigorous evaluation of the best
venom combinations. The flourishing field of proteomics has allowed a comprehensive and in depth
knowledge of the composition of many snake venoms (venomics), including some of the medically
most important species. In parallel, an increased understanding on the immunological relationships of
the various venom components has been also reached, by the combination of neutralization studies
and “antivenomics”, a field of research that harnesses the potential of proteomics for assessing the
immunoreactivity of antivenoms [25,28].
The complexity of snake venoms, and the consequent wide spectrum of pathological and
pathophysiological manifestations of envenomings due to the concerted actions of several toxin
types, represents a great challenge for the preclinical evaluation of the efficacy of antivenoms, as a prior
condition to the clinical evaluation of their safety and efficacy. The present review summarizes the
state-of-the-art in the field of preclinical evaluation of antivenoms, and presents some of the unsolved
issues that require further studies and developments.
2. Neutralization of Lethality: The Gold Standard in the Preclinical Assessment of
Antivenom Efficacy
Being lethality the ultimate consequence of snakebite envenoming, the neutralization of this effect
became the centerpiece of the evaluation of the preclinical efficacy of antivenoms since the dawn
of this immunotherapy (see [29,30]). Generally, mice are used in these tests [31,32], although some
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laboratories work with other species, such as guinea pigs [32]. Initially, the Median Lethal Dose (LD50)
of a particular venom is determined by administering various doses to groups of mice and recording
the number of dead animals within a predetermined time interval, usually 24 h or 48 h. LD50 is then
estimated by Probits [33], Spearman–Karber [34], or non-parametric tests [32]. For the assessment
of neutralization of lethality, a “challenge dose” of venom is selected, corresponding to a number of
LD50s (which usually range between 3 and 6 depending on the laboratory). Then, mixtures containing
a fixed concentration of venom and variable dilutions of the antivenom are prepared, and incubated.
Afterwards, aliquots of the mixtures, containing the challenge dose of venom, are injected in mice
using the same route of administration employed for the determination of the LD50. A control group of
animals receives the same dose of venom incubated with saline solution or with a solution containing
albumin. Deaths occurring within a specified time interval are recorded and neutralization is expressed
as Median Effective Dose (ED50), i.e., the volume of antivenom or the venom/antivenom ratio at which
50% of injected mice survived. Some quality control laboratories express the neutralizing efficacy in
terms of “potency” [35].
There are many variations in the way this test is performed in different laboratories, and this
introduces difficulties when comparing data coming from various sources. These variations include:
(a) The number of LD50s used as challenge dose. This has implications since the higher the number
of LD50s in the challenge dose, the lower the estimated antivenom efficacy [36]. Moreover, in some
cases, the challenge dose is defined as the Minimum Lethal Dose (MLD) [37]. (b) The strain and weight
of mice used in the tests, as some studies have revealed variations in the susceptibility of certain
strains to venoms [38,39]. (c) The route of venom injection. Most laboratories use the intravenous
(i.v.) route in the estimation of LD50 and ED50 [32], although others, especially in Latin America, use
the intraperitoneal (i.p.) route [35,40]. Different pathophysiological mechanisms, and hence different
toxins, may predominate in the overall toxicity depending on the route of injection (see below).
(d) The ways in which neutralization is expressed, that could be µL antivenom per challenge dose of
venom, mg venom per mL antivenom, µL antivenom per mg venom, or mg antivenom per mg venom,
and even the number of LD50s neutralized per mL antivenom, although the latter has been criticized
and is not recommended in the revised version of the WHO Guidelines for Production, Control and
Regulation of Snake Antivenom Immunoglobulins [41]. It is necessary to characterize in greater detail
the design, analytical properties, and factors affecting the outcome of these tests, since few studies
have been performed on this important topic [31,39,42,43].
Some works have approached the neutralization of lethality by using a protocol that resembles
the natural setting of snakebite more closely, i.e., by administering the antivenom after envenoming.
This type of “rescue protocol” involves the injection of a challenge dose of venom, followed by the i.v.
injection of various doses of antivenom [31,44,45]. ED50 is defined as the volume of antivenom which
protects 50% of injected mice. Despite its valid rationale, this protocol has not been introduced into
quality control laboratories because these tests are more difficult to standardize, and also since, in this
context, results are influenced by venom toxicokinetics and antivenom pharmacokinetics, and not just
the intrinsic antivenom neutralizing capacity [46]. However, despite not being implemented in the
routine quality control procedures, the information provided by this type of assessment is valuable to
understand neutralization in the context of the dynamics of envenoming (see Section 7).
3. The Need to Understand the Mechanisms of Toxicity in the Lethality Assay
Being the determination of LD50 and ED50 of such paramount relevance in the analysis of
antivenom preclinical efficacy, it is noteworthy that relatively few studies have addressed the
predominant mechanisms of toxicity in these tests and, hence, the venom activities that are being
assessed, vis-à-vis the pathophysiology of envenomings in the clinical setting. In the case of neurotoxic
venoms, such as those of elapid and some viperid species, clearly the cause of death is neuromuscular
paralysis and respiratory failure secondary to the action of pre- and/or post-synaptically acting
neurotoxins [47]. However, in other venoms, the situation is more complex. Procoagulant venoms,
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such as those of many viperids and some elapids, are likely to cause death by fulminant intravascular
thrombosis when injected by the i.v. route [48–50]. In contrast, when using the i.p. route, viperid
hemorrhagic venoms cause a massive extravasation leading to cardiovascular collapse, as shown for
the venom of Bothrops asper [51]. It is necessary to gain a better understanding on the main toxicity
mechanisms of medically-relevant venoms in the experimental conditions in which lethality and
neutralization tests are performed.
4. The Complex Pathophysiology of Snakebite Envenoming Demands a Wider Approach for the
Preclinical Testing of Antivenoms
Snakebite envenomings generally involve a rather complex pathophysiology, owing to the great
variety of toxins present in most venoms, as revealed by proteomic analysis [25]. Many species of the
family Elapidae, such as the mambas (Dendroaspis sp.), kraits (Bungarus sp.), coral snakes (Micrurus sp.),
and many cobras (Naja sp.) predominantly induce a neurotoxic effect secondary to the blockade of
neuromuscular transmission due to the action of neurotoxins [47]. In these cases, the study of the
neutralization of lethality is a good model to assess the preclinical efficacy of antivenoms. However,
in many other species, different pathological and pathophysiological activities of the venoms mediate
in the overall toxicity in humans and should be considered in the evaluation of antivenoms.
Envenomings by sea snakes, some terrestrial elapid species and the South American rattlesnake
are characterized by systemic myotoxicity, i.e., rhabdomyolysis, in addition to neurotoxicity [52,53].
Such massive muscular damage often causes acute kidney injury secondary to the deposition of large
amounts of myoglobin in the renal tubules. Many cobra venoms, such as those of the spitting species
in Africa and Asia, cause a predominantly local necrotizing effect in humans [54]. A number of elapid
species of Australia and Papua New Guinea contain, in addition to potent neurotoxins, prothrombin
activators that cause significant hemostatic disturbances and, in some cases, myotoxic PLA2s that
cause systemic myotoxicity and acute kidney injury [55]. The majority of viperid venoms, on the other
hand, induce local tissue damage (myonecrosis, dermonecrosis, hemorrhage, and edema) and systemic
alterations associated with coagulopathies, bleeding in various organs, hemodynamic disturbances,
and renal alterations [47,54,56]. Some of these effects may not result in lethality, but cause tissue
damage that may end up in permanent sequelae. In all these cases it is clear that the assessment of
the neutralization of lethality by antivenoms is insufficient for an integrated evaluation of antivenom
preclinical efficacy, and a wider set of neutralization assays is required. This view was incorporated in
the WHO Guidelines for Antivenoms, in which “essential” and “recommended” tests are described for
the preclinical assessment of antivenoms [32]. The evaluation of neutralization of lethality was defined
as the “essential” preclinical test, but supplementary tests, aimed at evaluating the neutralization of
other toxic activities, are recommended for new antivenoms and for introducing existing antivenoms
into new geographical settings [32]. These supplementary tests include assays for evaluating the
neutralization of hemorrhagic, necrotizing, in vitro procoagulant, in vivo defibrinogenating, myotoxic,
and neurotoxic activities, although in the WHO Guidelines it is mentioned that the lethality test is
reliable to predict neutralization of neurotoxicity [41]. A brief description of the methodologies used
for assessing these effects follows.
4.1. Hemorrhagic Activity
The assessment of the neutralization of hemorrhagic activity is important for most viperid venoms,
and also for some non-front fanged colubrid venoms of potential relevance in human envenomings,
such as those of Dispholidus typus and Rhabdophis sp. Since its development in 1960, the rodent
skin assay to assess hemorrhagic activity has become widely used for quantifying this effect and its
neutralization. The test was originally developed in rabbits [57], although most groups currently use
either rats [58] or, more often, mice [59]. Hemorrhagic activity is determined by injecting variable
amounts of venom intradermally in the abdominal region of the animals. After a time interval,
usually 2 h, animals are sacrificed, their skin removed, and the size of the hemorrhagic lesion in the
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inner side of the skin is measured. Hemorrhagic activity is expressed as the Minimum Hemorrhagic
Dose (MHD), defined as the dose of venom that induces a hemorrhagic area of 10 mm diameter [59].
One limitation of this procedure is that similar hemorrhagic areas might show different intensities
of hemorrhage. This can be circumvented by measuring the amount of hemoglobin present in the
hemorrhagic lesion [60]. For the study of neutralization by antivenoms, a challenge dose of venom
corresponding to five MHDs is used, and neutralization is expressed as ED50, i.e., the volume of
antivenom, or the venom/antivenom ratio, in which the size of the hemorrhagic spot is reduced by
50% [59].
4.2. Necrotizing Activity
Neutralization of necrotizing activity in the skin, i.e., dermonecrosis, is relevant in the case of
venoms that induce cutaneous necrosis, such as those of spitting cobras (Naja sp.) of Africa and
Asia [54,61]. The method is performed in rodents, usually rats or mice, and is based on the intradermal
injection, in the abdominal region, of solutions containing various venom doses. After 72 h, animals
are sacrificed, their skin removed, and the size of the necrotic lesion in the inner size of the skin
measured [58,62]. The Minimum Necrotizing Dose (MND) corresponds to the dose of venom inducing
a necrotic lesion of 5 mm diameter. For neutralization studies, a challenge dose of one MND is used [62].
Neutralization is expressed as ED50, i.e., the volume of antivenom, or the venom/antivenom ratio,
in which the size of the necrotic lesion is reduced by 50%.
4.3. In Vitro Coagulant Activity
Many snake venoms are procoagulant when added to plasma, by acting on several factors of the
coagulation cascade. In clinical cases, the most important consequence of this effect is consumption
coagulopathy and defibrinogenation, which may contribute to profuse bleeding [63]. The assessment
of the neutralization of this effect by antivenoms is important for many viperid and some Australian
elapid venoms. In vitro procoagulant activity is usually tested in human citrated plasma or in solutions
of bovine fibrinogen [58]. When using plasma, the test detects several types of procoagulants, such as
thrombin-like enzymes, and activators of factors X and prothrombin. When using fibrinogen solutions,
the assay detects only thrombin-like enzymes. Thus, for antivenom efficacy assessment the use of
citrated plasma is generally preferred. Various doses of venom are added to plasma, or fibrinogen,
previously incubated at 37 ◦C, the mixtures are kept at 37 ◦C, and the time when a firm clot is formed
is recorded. Activity is expressed as the Minimum Coagulant Dose-plasma (MCD-P), or the Minimum
Coagulant Dose-fibrinogen (MCD-F), i.e., the amount of venom that induces clotting of plasma, or
fibrinogen, in 60 sec [58,64]. For neutralization studies, a challenge dose of two MCDs is used [64].
Neutralization is expressed as Effective Dose (ED). Some authors define ED as the volume of antivenom,
or the venom/antivenom ratio, at which clotting is increased three times as compared to clotting times
of plasma, or fibrinogen, incubated with venom alone [64]. Another way to express ED is the lowest
volume of antivenom which completely prevents clotting [32].
4.4. Defibrinogenating Activity
In general, snake venoms that induce in vitro clotting of plasma are able to cause defibrinogenation
in vivo. This activity is assessed by injecting various doses of venom i.v. in mice. One hour after
envenoming, animals are bled by cardiac puncture or from the orbital venous plexus, under anesthesia.
Blood is placed in glass tubes and left undisturbed for 1 h at room temperature. At the end of this
period, tubes are gently tilted and the formation of a clot is observed. Activity is expressed as the
Minimum Defibrinogenating Dose (MDD), defined as the lowest venom dose which renders blood
unclottable in all mice injected; blood from all control mice receiving saline solution instead of venom
should clot [58,64]. For the study of neutralization, a challenge dose of two MDDs is used [64].
Neutralization is expressed as Effective Dose (ED), i.e., the minimum volume of antivenom, or the
venom/antivenom ratio, at which all blood samples clot after 1 h incubation [41,64].
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4.5. Myotoxic Activity
Many venoms of species of the families Elapidae and Viperidae induce local and, in some cases,
systemic myotoxicity, which is mostly caused by PLA2s [65]. Some elapid venoms, such as those of sea
snakes and Australian terrestrial species, and the venoms of few viperids, such as the South American
rattlesnake, induce systemic myotoxicity which may in turn contribute to acute kidney injury [55,66].
Many viperid venoms cause local myonecrosis [65]. Venom-induced myotoxicity can be studied by
histological analysis of affected muscle tissue. Quantitatively, it is feasible to estimate the extent
of myonecrosis by quantifying, in tissue sections, the total number of fibers and the number of
necrotic fibers, which are usually identified by the presence of hypercontraction of myofibrils. Thus,
a Necrotic Index can be obtained by dividing the number of necrotic fibers by the total number of
muscle fibers [67]. However, since histological analysis is time consuming and not all quality control
laboratories have facilities to process tissues, an alternative assay is the quantification of the plasma
or serum activity of the enzyme creatine kinase (CK), which is released from damaged muscle fibers
to the circulation [68]. Various venom doses are injected intramuscularly (i.m.) in the gastrocnemius
or thigh muscles of mice and, after 3 h, a blood sample is collected and the CK activity of plasma or
serum is determined. The Minimum Myotoxic Dose (MMD) is the amount of venom that increases
four times the CK activity, as compared to mice injected with saline solution [32,69]. For neutralization,
a challenge dose of 3 MMDs is used, and neutralization is expressed as Median Effective Dose (ED50),
i.e., the volume of antivenom, or the venom/antivenom ratio, at which CK activity is reduced by 50%
as compared to that of mice injected with venom alone [69].
4.6. Edematogenic Activity
Edema at the site of venom injection is characteristic of envenomings by vipers, and by some
cytotoxic elapids [54,61]. This effect can be studied experimentally by injecting various doses of venom
subcutaneously in the footpad of mice or rats. Then, at various time intervals, the increment in the
volume of the pad is assessed by either plethysmometry [70,71] or by measuring the thickness of the
injected pad with a low-pressure spring caliper [72]. These two techniques have largely replaced older
methods based on determining the weight of footpads of mice after euthanasia [73] since they only
allow the determination of edema at one time interval. The Minimum Edematogenic Dose (MED)
is the amount of venom that induces an increment of 30% in footpad volume or thickness 1 h after
injection [69]. For neutralization, a challenge dose of six MEDs has been used, and antivenom efficacy
(ED50) is the volume of antivenom, or venom/antivenom ratio, which reduces by 50% the edema
induced by venom alone [69].
4.7. Neurotoxic Activity
Various methods have been implemented to evaluate the inhibitory effect of snake venoms on
neuromuscular preparations ex vivo [74–77]. The time to reach either 50% or 90% neuromuscular
blockade is estimated. Neutralization studies are performed either by incubating venom and antivenom
before addition to the bathing solution or by first adding the venom to the medium, and then
applying various volumes of antivenom [78,79]. ED50 corresponds to the volume of antivenom, or the
venom/antivenom ratio, at which the neuromuscular blockade is reduced by 50%. This methodology
requires equipment and expertise which make it difficult to perform in routine quality control
laboratories. Hence, it is considered that the neutralization of lethality, in predominantly neurotoxic
venoms, is directly related to the neutralization of neurotoxicity [32]. Figure 1 summarizes the most
important effects that need to be tested for various types of snake venoms for the preclinical evaluation
of antivenom efficacy.
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Figure 1. Most relevant toxic activities induced by venoms of different snake groups that need to
be considered in the preclinical evaluation of antivenoms. Venoms of many elapid species, and few
viperids, mainly induce neurotoxicity, which is assessed by lethality. Sea snake venoms induce both
neurotoxicity and systemic myotoxicity. The main effect in envenomings by spitting cobras is cutaneous
necrosis, which has to be evaluated in addition to lethality. Several Australian terrestrial elapids, as well
as few rattlesnake venoms, induce neurotoxicity, myotoxicity and consumption coagulopathy, which
depends on their coagulant enzymes. Envenomings by many viperid species cause, in addition to
lethality, local tissue damage (hemorrhage and myotoxicity), and systemic effects associated with
bleeding and coagulopathy. Other pathophysiological alterations that would need to be considered
in the preclinical evaluation of antivenoms are thrombocytopenia, platelet hypoaggregation, acute
kidney injury, and systemic vascular capillary leakage syndrome. Reproduced from [46], copyright
2013 Elsevier.
5. Towards Expanding the Set of Laboratory Tests for the Evaluation of Antivenoms
In addition to the assays described above, there are other toxicological effects which play a relevant
role in snakebite envenomings and whose neutralization by antivenoms is important to assess.
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Examples are: (a) Cardiovascular alterations: Some studies have monitored the effects of venoms on
the mean arterial blood pressure after i.v. injection of venoms [80,81]. Alternatively, the increments in
the blood lactic acid concentration might be used to monitor the increment in anaerobic metabolism as
a consequence of reduced blood flow and ischemia in tissues [80]. (b) Thrombocytopenia and platelet
hypoaggregation: Alterations in platelet counts and function are important in envenomings by some
viperid species [82,83]. Thrombocytopenia can be assessed by administering various venom doses i.v.
and then, at 1 h, determining platelet counts in blood. The Thrombocytopenic Dose 50% corresponds
to the amount of venom that reduces blood numbers by 50% [84]. Likewise, platelet hypoaggregation
can be assessed by preparing platelet-rich plasma from envenomed animals, and assessing aggregation
after addition of agonists such as ADP or collagen [84,85]. (c) Acute kidney injury induced by a number
snake venoms: Studies have been performed using histological assessment of renal damage, alterations
in functional parameters renal perfusion system [86], and quantification of concentration of metabolites
in serum, such as creatinine, which are elevated in kidney injury [87]. Other clinically-relevant
effects for which laboratory tests have to be implemented are the thrombotic activity characteristic of
envenomings by the Caribbean species Bothrops lanceolatus and B. caribbaeus [88], the systemic leakage
syndrome described in envenomings by some populations of Daboia russelli [61], the hyponatremia
described in envenomings by Bungarus multicinctus [89], and the cardiotoxic effect induced by the
venom of stiletto snakes of genus Atractaspis [90]. It is necessary to standardize laboratory procedures
for modeling these and other venom activities and for assessing the neutralizing ability of antivenoms.
6. The Issue of Minimum Accepted Values of ED50 for Preclinical Neutralization Tests
There is a lack of international consensus on the acceptable limits for the preclinical neutralizing
ability of antivenoms other than the general concept that they have to neutralize the most relevant toxic
activities of the venoms they are supposed to neutralize. Thus, when evaluating an antivenom
preclinically, the first step seems to be a yes/no decision on whether an antivenom neutralizes
a particular effect, i.e., lethality, hemorrhagic activity, coagulant activity, etc. An antivenom which
proves ineffective for neutralizing a clinically-relevant toxic effect of a venom should not be accepted
for its clinical use. However, even in the case where neutralization is achieved, there are huge
differences in the values of ED50s between antivenoms. For example, when assessing the efficacy of
antivenoms distributed in sub-Saharan Africa in the neutralization of toxic effects of the venom of
Echis ocellatus, the majority of the antivenoms tested were able to neutralize the effects, but with wide
variations in their ED50. The case of neutralization of in vitro coagulant activity illustrates this point.
When expressed in terms of mg venom neutralized per mL antivenom, the most effective antivenom
had an ED50 of 12.88 ± 0.09 mg/mL, whereas the antivenom with the lowest efficacy had an ED50 of
0.1 ± 0.01 mg/mL, a 128 fold difference [91].
The majority of antivenoms raised against elapid venoms, which predominantly contain
antigenically-weak low molecular mass neurotoxins and PLA2s, have values of ED50 for the
neutralization of lethality ranging from 0.5 mg/mL to 1.5 mg/mL, although there are cases in
which higher potencies are achieved [50,92]. In contrast, antivenoms against viperid venoms,
whose most relevant toxins are SVMPs, serine proteinases and PLA2s, often have potencies of
2 mg/mL or above [40], although there are antivenoms with lower potencies being distributed [93].
Some Pharmacopoeias establish the potency values that antivenoms should have, but nevertheless
there is a lack of regulatory framework for antivenoms in many countries.
Several antivenoms used for the treatment of envenomings by Bothrops sp. in Latin America have
ED50s of 3 mg/mL or higher for lethality [40]. This has been established in a number of countries in
the region as the minimum acceptable level for antivenoms. In Australia, there is a required potency
for the various antivenoms used (defined as units per vial) [53]. However, there are other regions in
the world, such as sub-Saharan Africa, in which no parameters for antivenom acceptance have been
defined yet. Consequently, antivenoms of highly variable potencies are distributed [91,93]. Hence,
there is a need to establish acceptable limits of potency of antivenoms at the preclinical level, a task
Toxins 2017, 9, 163 9 of 22
that demands the concerted work of laboratory scientists, clinical researchers, regulatory agencies,
antivenom manufacturers, and the WHO and its regional offices. Regional workshops involving these
stakeholders are required to define the acceptable potencies for antivenoms and the preclinical tests
that should be performed before an antivenom is introduced for clinical use.
7. The Impact of Venom Toxicokinetics and Antivenom Pharmacokinetics in the Effectiveness of
Antivenoms: Pharmacokinetic-Pharmacodynamic Relationships
As discussed above, the most common way to test antivenom efficacy at the preclinical level is
based on a protocol that involves incubating venom and antivenom before testing in the in vitro or
in vivo assays described. However, this experimental design does not take into account the complex
pharmacokinetic-pharmacodynamic interactions involved in venom neutralization in vivo. Several
groups have studied the neutralization of snake venoms using a protocol that involves the independent
injection of venom and antivenom, thus simulating the real circumstances of snake bites in which
pharmacokinetic parameters are critical. The results obtained in these studies highlight relevant
aspects of venom neutralization since there is frequently a mismatch between the toxicokinetics of
venom components and the pharmacokinetics of antivenom antibodies or antibody fragments. Toxins
and antibodies usually have different volumes of distribution and vary in the time needed to reach
equilibrium in their distribution space [94]. Likewise, venom toxins act on their targets in the tissues
or blood at variable time-courses.
One aspect of snakebite envenoming in which this mismatch is notorious has to do with the action
and neutralization of toxins inducing local tissue damage in viperid venoms and cytotoxic elapid
venoms [95]. Once injected in a natural bite, the toxins responsible for local pathology, especially
hemorrhagic SVMPs, myotoxic PLA2s, and cytotoxic three-finger toxins act very rapidly and induce
skeletal muscle necrosis, degradation of extracellular matrix, dermonecrosis, and hemorrhage within
minutes of injection [96,97]. Therefore, even when antivenoms are administered by the i.v. route
immediately after envenoming, the neutralization of these local effects is only partial [59,98,99].
In these circumstances, the distribution of antivenom antibodies to the affected tissue is limited, and
the deleterious action of the toxins occurs rapidly. This is the case even when using antivenoms able to
neutralize these local effects when incubated with venom prior to injection [95,98]. Furthermore, local
i.m. injection of antivenom at the site of tissue damage did not improve the neutralization as compared
to i.v. administration [98], probably due to constraints in the diffusion of antibodies in a damaged
tissue environment.
When similar, “rescue-type” experiments have been performed to assess the neutralization of
neurotoxicity, i.e., lethality, induced by elapid venoms, a rapid i.v. administration of antivenoms after
envenoming prevents death. However, effectiveness of antivenoms decreases as the time lapse between
envenoming and antivenom administration increases [45,79,100]. There is, therefore, a window of time
when antivenom antibodies are able to bind toxins in the circulation before they reach their targets at
the neuromuscular junctions. Thus, even when this type of “rescue” experiments are not routinely
performed in the preclinical assessment of antivenoms, they bring valuable information regarding the
dynamics of envenoming and therapy, and raise research issues related to the need of alternative ways
to improve snakebite envenoming treatment such as, for example, the search for natural and synthetic
inhibitors that could circumvent some of the limitations of antibodies, particularly regarding local
tissue damage [101].
8. Implementation of the 3Rs in Antivenom Testing
The need to use animals in the evaluation of antivenoms, and the inherent suffering that venoms
induce in these tests, have raised concerns about the need to reduce both the number of animals
used and the pain associated with venom toxicity and neutralization tests. The WHO guidelines
of antivenoms [32] place special emphasis on this aspect, and efforts by several groups are being
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performed to promote the concept of the 3Rs (Replacement, Reduction, and Refinement) in antivenom
development and quality control.
The search for in vitro tests that would substitute in vivo assays, such as lethality and
determination of hemorrhagic, myotoxic, dermonecrotic, and defibrinogenating activities, has been
difficult due to the complex biochemical and toxicological nature of snake venoms, whereby toxicity is
often determined by several toxins acting together in synergistic and additive fashions [102,103].
For neurotoxic venoms, the use of ex vivo neuromuscular preparations is useful for assessing
neuromuscular blockade and its neutralization [79,104,105]. However, this procedure is difficult
to implement and is usually performed in specialized laboratories and not in antivenom development
and quality control laboratories. In some cases, in vitro immunochemical and enzymatic tests have
shown good correlation with the neutralization of lethality. Examples are enzyme immunoassays for
some viperid venoms [106,107]. In this case, the development of assays to assess the antibody titers
against the proteins responsible for the main toxicity in a venom is likely to give better results than
using the crude venom. Two cases that illustrate this principle are the venom of the South American
rattlesnake Crotalus durissus terrificus, where toxicity largely depends on the neurotoxic and myotoxic
action of the heterodimeric PLA2 complex crotoxin [105], and the venom of some neurotoxic elapids,
such as Naja kaouthia, where toxicity depends mostly on the action of few α-neurotoxins [108].
For predominantly neurotoxic venoms, the Toxicity Score of venom components is a useful tool [109]
which includes proteomic and functional analyses of fractions, a field known as Toxicovenomics [110].
Other in vitro immunological assays used to assess antivenom reactivity against venoms include
size-exclusion chromatography [111] and turbidimetry [112]. The advent of “antivenomics”, with
its powerful analytical potential, has constituted a significant leap forward in the in vitro preclinical
assessment of antivenoms, and is discussed in the next section of this review.
For Bothrops asper venom, the neutralization of in vitro activities, such as PLA2 and procoagulant
effects, has been shown to correlate with neutralization of lethality [51,113]. Thus, despite the fact
that it is difficult to substitute the lethality test in the final quality control of antivenom efficacy, these
surrogate tests may greatly reduce the number of mice used for following the development of antibody
titers in horses, or help in reaching a preliminary yes/no decision on whether an antivenom is effective
against a venom. Likewise, the second edition of the WHO guidelines on antivenoms presents the use
of immunochemical tests, such as ELISAs or antivenomics, as screening tests of antivenom efficacy
before using animals. Each laboratory should develop its own standards and limits of acceptance,
mainly based on studies of correlation between these in vitro assays and the in vivo toxicity tests [41].
Effects other than lethality can be also substituted by in vitro assays. The myotoxic activity of
snake venom PLA2s and PLA2 homologs, as well as of cytotoxins of the three finger toxin family,
depends on their ability to directly attack the integrity of the plasma membrane of skeletal muscle
fibers [65,114]. Thus, the use of myoblast/myotube cell culture systems is a suitable way to assess the
myotoxic activity of venoms and myotoxins and its neutralization by antivenoms [115,116]. Likewise,
renal toxicity by venoms is partially dependent on their cytotoxic effects on renal cells [86], although the
pathophysiology of acute kidney injury in these envenomings also involves hemodynamic alterations
and intravascular coagulation [117]. On the other hand, the hemostatic alterations of many venoms,
associated with a consumption coagulopathy and defibrinogenation, is largely due to the action of
procoagulant venom components on fibrinogen or coagulation factors II, V or X [63]. Thus, in vitro
estimation of the clotting activity of venom on human citrated plasma [58,64] is likely to be a good
surrogate test for defibrinogenating activity. In contrast, it has been difficult to develop in vitro assays
that correlate with hemorrhagic activity since, although hemorrhage depends on proteinase action
of SVMPs, there is no correlation with hemorrhage when this activity is tested on commonly used
substrates, such as azocasein. It is suggested that physiologically-relevant substrates, such as type IV
collagen, should be tested, owing to the relevance of hydrolysis of this basement membrane component
in the pathogenesis of microvessel damage [118]. The use of chicken embryos at a developmental
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stage prior to the development of pain sensitivity has been proposed for studying neutralization of
hemorrhagic activity of venoms [119].
“Humane” tests for assessing lethality and its neutralization have been developed. Preliminary
dose-finding tests, using one mouse per dose, are recommended when first assessing the toxicity of
a venom [32]. This allows the selection of appropriate range of venom doses for estimating the LD50.
Likewise, some methods establish a final observation time of 8 h, after which all mice are euthanized.
Depending on the condition of the animals, mice showing signs of severe envenoming are euthanized
at any time before 8 h [120]; this reduces the time of observation and, therefore, the suffering. Caution
should be exercised, nevertheless, when using this method, as observations in our laboratory with
several venoms indicate that different results are obtained with this method as compared to a final
observation time of 24 h (our unpublished data).
Another important consideration is the use of analgesia, especially in venoms that induce severe
pain associated with tissue damage, such as most viperid venoms and some elapid venoms [121].
A study with Bothrops asper venom demonstrated that the prophylactic use of the analgesics morphine
or tramadol do not affect the outcome of the determination of lethal, hemorrhagic, myotoxic,
edema-forming and defibrinogenating activities [51,122]. It is necessary to validate the use of these
and other analgesics against different venoms, both in terms of their analgesic potential and assessing
whether they do not affect the results of toxicity tests. Figure 2 depicts some of the possibilities of
implementing the 3Rs concept in the preclinical evaluation of antivenoms.
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9. Antivenomics: Harnessing the Analytical Potential of Proteomics for the Evaluation
of Antivenoms
The understanding of the composition of snake venoms has grown exponentially in the last decade
owing to the use of mass spectrometry-based methodologies to investigate venom proteomics [123,124].
A large number of venoms have been analyzed using this analytical platform and a fascinating view of
the complexity and inter- and intra-species variability has emerged [20,125]. This explosive volume
of information has enriched the study of venoms from both biological and medical perspectives,
and has identified hitherto unknown venom components whose structures and actions need to be
investigated [22,25].
A straightforward application of the body of knowledge gained through the venomics platform is
the analysis of the immune reactivity of antivenoms against venoms, a field coined “antivenomics” [126].
Antivenomics is translational venomics, a proteomics-based protocol to quantify the extent of
cross-reactivity of antivenoms against homologous and heterologous venoms. In its current format,
the so-called “second generation antivenomics” platform [127] (Figure 2), antivenom molecules, whether
whole antibodies or antibody fragments, are covalently immobilized onto a chromatographic matrix,
the venom to be analyzed is pumped through the immunoaffinity column, and the unbound material
washed clear prior to elution of the retained venom molecules by alteration of the mobile phase
conditions that weaken the antibody-antigen interaction. Non-retained and retained protein mixtures
are then separated by reverse phase HPLC using the same conditions employed for the proteomic
analysis of the crude venom. Quantitative comparison of reverse-phase HPLC chromatograms of whole
venom and the immunoaffinity column eluates provides thus qualitative and quantitative information
on both the set of toxins bearing antivenom-recognized epitopes and those toxins exhibiting poor
immunoreactivity. For each chromatographic fraction, the percentage of retained protein can be
estimated by the equation:
% retained proteins = [retained/(retained + non-retained)] × 100
Maximum binding capacity of an antivenom for the different venom antigens can be estimated
through a series of experiments where the amount of venom pumped through the immunoaffinity
column is varied to estimate the µg of each venom component per mg antivenom protein that saturates
their specific antibody binding sites [91].
Despite its recent introduction, the usefulness and validity of antivenomics to complement the
in vivo standard preclinical assays of neutralization of lethality and toxic activities by homologous
and heterologous antivenoms has been extensively demonstrated in a growing number of applications
aimed at assessing the immunological profiles of antivenoms from different manufacturers and
countries (see for example [91,93,128–132]). The combination of antivenomics and in vivo and
in vitro neutralization tests constitutes thus a powerful toolbox that provides a robust evaluation
of antivenom preclinical efficacy [128]. In this regard, the WHO guidelines of antivenoms highlights
that antivenomics may be used as a way to assess whether an antivenom has the potential to be
effective against a particular venom, before initiating in vivo toxicity tests, as a way to reduce the use
of mice in the preclinical testing of antivenoms [41].
A number of experimental parameters that may potentially affect the performance of an antivenomics
affinity column have been pointed out [133]. To minimize potential problems while maximizing the
analytical capacity of antivenomics, the second generation protocol has been expanded. “Third
generation antivenomics” is presented in this Special Issue. Figure 3 depicts the basic protocol for
antivenomics and some examples of antivenomic analysis with antivenoms.
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Figure 3. Cartoon of the “second generation” antivenomics workflow [127]. Panels (A) and (B) illustrate,
respectively, the generation of the immunoaffinity (a) and control antibody (d) columns, and the steps
of the antivenomic protocol to assess which toxins show immunoreactivity towards the immobilized
antivenom molecules (c) and which do not bind to the immunoaffinity column (b). Mock matrix
and control IgG columns, run in parallel to the immunocapture experiment, serve as specificity controls.
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Panel (C) displays three immunoaffinity experiments using venoms of snakes from different families:
antivenomic analysis of D. typus (Colubridae: Colubrinae) venom against CroFab™ antivenom
(left) [134], antivenomic analysis of P. papuanus (Elapidae) venom against Australian antivenom
(middle) [132], and antivenomic analysis of B. diporus (Viperidae: Crotalinae) venom against Butantan
pentabothropic antivenom (right) [135]. Chromatograms labeled “a” display reference RP-HPLC
separation of the venom proteins. Major protein classes identified in the different chromatographic
fractions are highlighted (3FTx, three-finger toxin; PLA2, phospholipase A2; CRISP, cysteine-rich
secretory protein; SVSP, snake venom serine proteinase; PIII-SVMP, snake venom metalloproteinase
of class PIII; CTL, C-type lectin-like molecule; LAO, L-amino acid oxidase; VAP, vasoactive peptide;
SVMPi, tripeptide inhibitor of SVMPs). Chromatograms “b” and “c” display, respectively, reverse-phase
separations of the immunocaptured and the non-bound column fractions recovered from the
immunoaffinity columns. Chromatograms “d” and “e” show, respectively, reverse-phase HPLC
separations of the venom components recovered in the bound fractions of mock matrix and control
IgG columns.
10. The Need of International Partnerships to Evaluate Antivenoms on a Global Basis and to
Strengthen National Regulatory Agencies
As discussed in the previous sections, an integrated assessment of the preclinical efficacy of
antivenoms should be designed based on the main pathophysiological effects induced by the venoms to
be analyzed. Routine quality control sections in antivenom manufacturing laboratories and regulatory
agencies are seldom prepared to perform the whole set of tests described above, and usually carry out
only the neutralization of lethality test; in the case of regulatory agencies in many countries even this
basic assay is not performed. This raises the possibility that some antivenoms might not be effective to
neutralize the main toxic activities of venoms which they are supposed to neutralize, this becoming
a critical issue from a public health perspective.
This situation can be confronted through international partnerships whereby a network of
laboratories, mostly of research groups, set up the methodological platforms described in this review,
and develop new methods for the assessment of antivenom efficacy. In this way, the antivenoms
deployed in various regions of the world could be independently tested against relevant venoms of
snakes inhabiting the regions where these antivenoms are distributed. This type of concerted effort will
provide solid evidence of the preclinical efficacy, or inefficacy, of antivenoms. These sort of cooperative
studies have been performed in Latin America over the years, and have provided valuable information
on the scope of efficacy of antivenoms (see for example [36,40,69,136,137]. More recently, the efficacy
of seven antivenoms distributed in sub-Saharan Africa has been studied against the venom of Echis
ocellatus using neutralization tests and antivenomics [91,93]. Similar assessments have been performed
in Asia [138], Australia [139] and Papua New Guinea [79,132]. It is necessary to expand these efforts in
order to generate a complete picture of the preclinical spectrum of efficacy of antivenoms in the world.
Although this is a formidable challenge, it is possible to achieve it through international partnerships
under the coordination of the WHO or organizations such as the Global Snakebite Initiative [8,140].
The issue of developing expertise at national regulatory agencies on the preclinical efficacy
of antivenom is of outmost relevance. There have been reports of acquisition, by national health
authorities, of antivenoms which are not effective against local snake venoms due to the lack of
appropriate analysis of the products (see for example [26]). In some cases, the only criteria for
acceptance of an antivenom is the description of the product provided by the manufacturer, and its
price. International efforts should be promoted to enhance the capacity of national regulatory agencies
for the registration and acceptance of antivenoms. This has to include, at least, a basic understanding
on antivenom manufacture and preclinical efficacy and, ideally, the establishment of national or
regional quality control laboratories that assess the neutralization of venom lethality by antivenoms.
The case of Brazil is noteworthy, whereby a national quality control laboratory, the Instituto Nacional
de Controle de Qualidade em Saúde (INCQS), evaluates all antivenom batches produced by the
various manufacturing laboratories on the country [35]. The improvement of the capacities of national
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regulatory agencies could be achieved through international workshops organized by the WHO and
its regional offices, with the collaboration of international experts. The combination of strengthened
national regulatory agencies and a thorough study of the preclinical efficacy of antivenoms by research
networks will be significant leaps forward in the rigorous evaluation of antivenoms, as a way to ensure
the safety and efficacy of these products for their clinical use.
11. Preclinical Testing Should Be Followed by Appropriate Clinical Assessment of Efficacy and
Safety of Antivenoms
As discussed along this review, a meticulous preclinical testing of antivenom efficacy should be
performed before the acceptance of a new antivenom, or the use of an existing antivenom in a new
geographical setting. Nevertheless, demonstration of preclinical efficacy does not necessarily imply
that an antivenom can be directly introduced for human use. As indicated in the WHO Guidelines of
antivenoms [32,41], appropriate evaluation of antivenoms at the clinical level is necessary to ensure
efficacy and safety. Even though the use of preclinical models described in this review are highly useful
at predicting whether an antivenom is effective against a snake venom, there might be differences in
the response of mice and humans to venoms and to antivenom treatment; hence, the performance of
clinical trials is required as a final step in antivenom evaluation.
Clinical trials of antivenoms are designed to address three main issues: (a) the optimal initial dose;
(b) efficacy, i.e., the ability of antivenom to control the main clinical manifestations of envenoming; and
(c) safety, i.e., the incidence and severity of early and late adverse reactions [32]. Dose-finding studies
are usually followed by randomized, controlled trials in which the new antivenom is compared to
another antivenom already in use or, in its absence, two doses of the new antivenom can be compared.
Observational studies can be performed when assessing an existing antivenom for its use in a new
geographical location. In addition, once an antivenom starts to be distributed, it is important to
perform post-marketing surveillance, or phase IV studies, in order to detect aspects of efficacy and
safety that had been unnoticed during regular phase II and III studies [32].
12. Concluding Remarks
Owing to the biochemical, toxicological and immunological complexity of snake venoms, and their
highly diverse patterns of regional and ontogenetic variability, the evaluation of the preclinical efficacy
of antivenoms represents a difficult but rather important task. A methodological platform exists for
such analyses, based on a set of relatively simple laboratory techniques that combines in vivo and
in vitro assays, including neutralization tests and immunochemical assessments, e.g., antivenomics.
However, these assays are often implemented in research laboratories and not in the quality control
laboratories of manufacturers and regulatory agencies. This raises the need for developing concerted
international efforts to thoroughly analyze the spectrum of preclinical efficacy of many antivenoms
currently in use in various regions of the world, as well as new antivenoms being developed.
Novel preclinical tests are required in order to evaluate venom activities that play a key role
in the pathophysiology of some envenomings, such as assays for cardiovascular and renal toxicity.
Likewise, the philosophy of the 3Rs needs to be actively promoted in the field of antivenoms to reduce
the use of animals, systematically introduce the use of analgesics, and develop novel in vitro assays in
substitution of in vivo tests. In parallel, national regulatory agencies need to be strengthened through
workshops and training programs of diverse sorts, with the goal of ensuring that antivenoms being
introduced and used in the clinics are safe and effective. These issues pose significant challenges to the
research, regulatory, and public health international communities and organizations.
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